287 related articles for article (PubMed ID: 25012985)
1. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
Kulke MH; O'Dorisio T; Phan A; Bergsland E; Law L; Banks P; Freiman J; Frazier K; Jackson J; Yao JC; Kvols L; Lapuerta P; Zambrowicz B; Fleming D; Sands A
Endocr Relat Cancer; 2014 Oct; 21(5):705-14. PubMed ID: 25012985
[TBL] [Abstract][Full Text] [Related]
2. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
Kulke MH; Hörsch D; Caplin ME; Anthony LB; Bergsland E; Öberg K; Welin S; Warner RR; Lombard-Bohas C; Kunz PL; Grande E; Valle JW; Fleming D; Lapuerta P; Banks P; Jackson S; Zambrowicz B; Sands AT; Pavel M
J Clin Oncol; 2017 Jan; 35(1):14-23. PubMed ID: 27918724
[TBL] [Abstract][Full Text] [Related]
3. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Pavel M; Gross DJ; Benavent M; Perros P; Srirajaskanthan R; Warner RRP; Kulke MH; Anthony LB; Kunz PL; Hörsch D; Weickert MO; Lapuerta P; Jiang W; Kassler-Taub K; Wason S; Fleming R; Fleming D; Garcia-Carbonero R
Endocr Relat Cancer; 2018 Mar; 25(3):309-322. PubMed ID: 29330194
[TBL] [Abstract][Full Text] [Related]
4. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.
Pavel M; Hörsch D; Caplin M; Ramage J; Seufferlein T; Valle J; Banks P; Lapuerta P; Sands A; Zambrowicz B; Fleming D; Wiedenmann B
J Clin Endocrinol Metab; 2015 Apr; 100(4):1511-9. PubMed ID: 25636046
[TBL] [Abstract][Full Text] [Related]
5. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
Weickert MO; Kaltsas G; Hörsch D; Lapuerta P; Pavel M; Valle JW; Caplin ME; Bergsland E; Kunz PL; Anthony LB; Grande E; Öberg K; Welin S; Lombard-Bohas C; Ramage JK; Kittur A; Yang QM; Kulke MH
Clin Ther; 2018 Jun; 40(6):952-962.e2. PubMed ID: 29724499
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
Anthony LB; Kulke MH; Caplin ME; Bergsland E; Öberg K; Pavel M; Hörsch D; Warner RRP; O'Dorisio TM; Dillon JS; Lapuerta P; Kassler-Taub K; Jiang W
Oncologist; 2019 Aug; 24(8):e662-e670. PubMed ID: 30651397
[TBL] [Abstract][Full Text] [Related]
7. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
Strosberg J; Joish VN; Giacalone S; Perez-Olle R; Fish-Steagall A; Kapoor K; Dharba S; Lapuerta P; Benson AB
Oncologist; 2019 Nov; 24(11):1446-1452. PubMed ID: 31189618
[TBL] [Abstract][Full Text] [Related]
8. Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea.
Lyseng-Williamson KA
Drugs; 2018 Jun; 78(9):941-950. PubMed ID: 29931594
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach.
Gelhorn HL; Kulke MH; O'Dorisio T; Yang QM; Jackson J; Jackson S; Boehm KA; Law L; Kostelec J; Auguste P; Lapuerta P
Clin Ther; 2016 Apr; 38(4):759-68. PubMed ID: 27041406
[TBL] [Abstract][Full Text] [Related]
10. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.
Anthony L; Ervin C; Lapuerta P; Kulke MH; Kunz P; Bergsland E; Hörsch D; Metz DC; Pasieka J; Pavlakis N; Pavel M; Caplin M; Öberg K; Ramage J; Evans E; Yang QM; Jackson S; Arnold K; Law L; DiBenedetti DB
Clin Ther; 2017 Nov; 39(11):2158-2168. PubMed ID: 29074312
[TBL] [Abstract][Full Text] [Related]
11. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Masab M; Saif MW
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1055-1062. PubMed ID: 29051994
[TBL] [Abstract][Full Text] [Related]
12. Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues.
Kasi PM
Drugs Today (Barc); 2018 Jul; 54(7):423-432. PubMed ID: 30090879
[TBL] [Abstract][Full Text] [Related]
13. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
Dillon JS; Kulke MH; Hörsch D; Anthony LB; Warner RRP; Bergsland E; Welin S; O'Dorisio TM; Kunz PL; McKee C; Lapuerta P; Banks P; Pavel M
J Gastrointest Cancer; 2021 Mar; 52(1):212-221. PubMed ID: 32146619
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Martínez-Sáez O; Grande E
Oncologist; 2016 Jun; 21(6):701-7. PubMed ID: 27107003
[TBL] [Abstract][Full Text] [Related]
15. Telotristat ethyl (Xermelo) for carcinoid syndrome diarrhea.
Med Lett Drugs Ther; 2017 Jul; 59(1525):119-120. PubMed ID: 28699933
[No Abstract] [Full Text] [Related]
16. Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.
Dillon JS; Chandrasekharan C
Future Oncol; 2018 May; 14(12):1155-1164. PubMed ID: 29350062
[TBL] [Abstract][Full Text] [Related]
17. Telotristat ethyl: a new option for the management of carcinoid syndrome.
Lamarca A; Barriuso J; McNamara MG; Hubner RA; Valle JW
Expert Opin Pharmacother; 2016 Dec; 17(18):2487-2498. PubMed ID: 27817224
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR.
Cella D; Beaumont JL; Hudgens S; Marteau F; Feuilly M; Houchard A; Lapuerta P; Ramage J; Pavel M; Hörsch D; Kulke MH
Clin Ther; 2018 Dec; 40(12):2006-2020.e2. PubMed ID: 30477789
[TBL] [Abstract][Full Text] [Related]
19. Does Telotristat Have a Role in Preventing Carcinoid Heart Disease?
Herrera-Martínez AD; Fuentes-Fayos AC; Sanchez-Sanchez R; Montero AJ; Sarmento-Cabral A; Gálvez-Moreno MA; Gahete MD; Luque RM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396713
[TBL] [Abstract][Full Text] [Related]
20. Developments in the treatment of carcinoid syndrome - impact of telotristat.
Chan DL; Singh S
Ther Clin Risk Manag; 2018; 14():323-329. PubMed ID: 29503551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]